Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Finasteride can treat prostatic haematuria, but its use is controversial.

This review discusses medical treatments for lower urinary tract symptoms suggestive of benign prostatic hyperplasia, focusing on their effects, side-effects, and implications for treatment goals, but reports no new clinical results.

This article discusses the side effects of androgen deprivation therapy for nonmetastatic prostate cancer, highlighting the need for clinical trials to systematically study these effects.

This study observed that despite the increase in nocturia cases from 2016 to 2021, the use of pharmacotherapy for the condition declined, suggesting potential undertreatment.

This study found that depression, anxiety, and sleep disturbance were associated with male lower urinary tract symptoms, but these factors did not predict improvement after evaluation and treatment over time.

This editorial comment references research on finasteride's effects on urinary retention and surgical needs in benign prostatic hyperplasia but reports no new findings.

Men's age, urinary symptoms, and heart health risks create different types of erectile dysfunction.

This review discusses the impact of COVID-19 on urological treatment approaches, including the heightened severity of LUTS in men with urological issues and emphasizes the importance of adhering to treatment protocols.

The authors concluded that components of metabolic syndrome were strongly associated with severe lower urinary tract symptoms in Latin American men, while alopecia was not an independent predictor.

This review examines the cognitive effects of medications for lower urinary tract symptoms and indicates that muscarinic antagonists, particularly oral oxybutynin, pose the highest risk for cognitive impairment.

This study concluded that male patients with improved lower urinary tract symptoms may have a lower risk of death, suggesting a potential benefit of treating symptoms beyond just managing patient discomfort.

This review examines microbial production and applications of gluconic acid, focusing on the enzymatic processes involved, and offers no new experimental results.

This review discusses lesser-known concerns in transgender dermatology, including neovaginal issues, neoplastic and autoimmune conditions, and the effects of unapproved injectable substances, but reports no new clinical findings.

This review discusses the potential risks of ejaculatory dysfunction associated with both medical and surgical treatments for lower urinary tract symptoms due to benign prostatic hyperplasia and their implications for male fertility, but it reports no new clinical results.

This article highlights the complexity of diagnosing hyponatremia in older adults, emphasizing the need to evaluate urinary tract obstruction, medication effects, and age-related changes rather than relying solely on spot urinary values.

This review details the prevalence and management of ejaculatory disorders in men with benign prostatic hyperplasia-related urinary symptoms and highlights the importance of preserving peri-montanal tissue during treatment to maintain antegrade ejaculation.

This reply argues that children with isolated extraordinary daytime frequency do not require extensive testing or aggressive pharmacologic treatments, noting potential negative effects of oxybutynin.

This study found that metabolic syndrome significantly affects the response to benign prostatic hyperplasia medications, impacting clinical outcomes such as symptom scores, prostate volume, and quality of life among male patients.

This review outlines common dermatological disorders in transgender patients related to hormone therapy and surgeries but presents no new clinical findings; the authors emphasize the need for inclusive healthcare training.

This case report discusses an instance of cystitis caused by the chemotherapy drug Cytoxan, with no new findings reported.

This article reviews the diagnostics and medical transition options for adults with gender incongruence, reports no new clinical results, and highlights the importance of primary care knowledge in managing these patients.

This review covers gynecologic examination challenges and normal anatomical variations in prepubertal girls, emphasizing the importance of distinguishing common benign conditions from rare abuse cases; it presents no new experimental findings.

This review discusses underactive bladder, highlighting its poorly understood nature, diagnostic challenges, and limited treatment effectiveness, and reports no new clinical results.

The authors discuss BPH treatment options and highlight that while medications can manage symptoms, recent minimally invasive procedures may offer promise for elderly males who are not surgical candidates or wish to avoid surgery.

This review discusses the prevalence and treatment of benign prostatic hyperplasia and reports no new findings; it emphasizes considering side effects and comorbidities in therapy choices.

Finasteride may cause breast enlargement, low testosterone a risk factor.

This study found that while new treatments like Optilume, Rezum, and Aquablation have minimal risks of sexual dysfunction, they offer less improvement in lower urinary tract symptoms compared to traditional surgeries like TURP, though Aquablation does reduce ejaculatory dysfunction more effectively than TURP.

This article reviews guidelines and medications for treating benign prostatic hyperplasia but presents no new clinical results.